Impact Biomedical Inc. has announced a significant merger with Dr. Ashleys Limited, resulting in a newly formed entity that will trade on the NYSE American under the name "Dr Ashleys Limited." This strategic move will see Dr. Ashleys acquire Impact Biomedical through a reverse merger, integrating Impact Biomedical's intellectual property portfolio into Dr. Ashleys' research and development efforts. The merger aims to accelerate the development of innovative pharmaceutical treatments and expand their global reach. Dr. Kanans Visvanats, Director of Dr. Ashleys Limited, emphasized the milestone's importance in bringing groundbreaking therapies to patients worldwide. Frank D. Heuszel, CEO of Impact Biomedical Inc., expressed excitement about the collaboration, highlighting Dr. Ashleys' global reach and resources that will help bring their innovations to market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.